Background: Small hepatocellular carcinomas (HCC ≤3 cm) are generally considered
| INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Its incidence has doubled in the past 20 years, making it the second leading cause of cancer death. 1 It is estimated that by 2020 the number of HCC cases in Europe and the USA will reach 78 000 and 27 000, respectively. 2 Management of HCC has significantly improved over the last decade as a result of better knowledge of HCC behavior, improvements in staging systems and treatment algorithms, and emerging therapeutic options. 3 One of the most reliable and widely adopted methods for staging HCC is the Barcelona Clinic Liver Cancer (BCLC) system, which stratifies patients according to the characteristics of the tumor, underlying liver disease and performance status. 4 HCC diameter value "3 cm or less (≤3 cm)" has a major impact for treatment choice in both the BCLC system and the 3rd Japan Society of Hepatology (JSH)-HCC guidelines. 5 Percutaneous ablation therapy such as radiofrequency ablation (RFA) and hepatic resection (HR) are equally recommended for HCC ≤3 cm. The reason why HCC ≤3 cm would be proposed for RFA was not clear, although two reasons can be considered. One is that HCC ≤3 cm is thought to have low malignant potential, and the other is the limitation of the safety margin for ablation.
Many reports have noted the heterogeneity of small HCC ≤3 cm, and some of these tumors display microvascular invasion (MVI) ranging from 18.1% to 37.0%, which indicated locally advanced HCC. [6] [7] [8] We previously reported that HR with a wide margin (>0.5 cm) led to better survival in patients with solitary HCC ≤2 cm that displayed MVI. To realize personalized treatment for small HCC, the establishment of reliable predictions for MVI in HCC ≤3 cm is very important.
Here, we present a retrospective analysis of predictors of MVI in single HCC ≤3 cm, and of survival in patients with single HCC 
| Clinical characteristics of HCC ≤3 cm with and without MVI
Comparisons of background characteristics between the MVI (À) group (n = 246) and the MVI (+) group (n = 168) are summarized in Table 1 . No variables showed significant differences between the two groups in background characteristics such as age, BMI, and liver function tests.
Comparisons of surgical factors between the two groups are summarized in Table 2 . Resected volume was significantly larger in the MVI (+) group (99 vs 73 g, P = .0071), and the rate of anatomical HR was higher in the MVI (+) group (36 vs 28%, P = .0993).
Mean duration of hospital stay was significantly longer in the MVI (+) group (18 vs 16 days, P = .0414).
Comparisons of tumor-related factors between the two groups are summarized in Table 3 . Variables of the MVI (+) group more often showed features of advanced tumor stage, such as tumor diameter (2.2 vs 2.0 cm; P < .0001), invasive gross type (46 vs 6%; P < .0001), poorly differentiated (33 vs 13%; P < .0001), fc-inf (+) (63 vs 31%; P < .0001), and higher DCP level (124 vs 48 mAU/mL; P = .0031).
| Independent risk factors or predictors for MVI in HCC ≤3 cm
Results of multivariate analysis with stepwise logistic regression analysis are summarized in Table 4 . Independent risk factors for MVI were invasive gross type (odds ratio 13.68), fc-inf (+) (odds ratio 4.11), and tumor diameter ≥2 cm (odds ratio 1.96). As for predictive factors for MVI which can be evaluated preoperatively, multivariate analysis (Table 5) showed that all three factors were independently significant predictors for MVI: tumor diameter ≥2 cm (odds ratio 1.84), AFP ≥200 ng/mL (odds ratio 1.82), and DCP ≥40 ng/mL (odds ratio 1.79).
| Criterion for predicting MVI in HCC ≤3 cm
Sensitivity and positive predictive value (PPV) of our predictors are summarized in Table 6 
| Survival of patients matching the criterion for predicting MVI in HCC ≤3 cm
In 563 patients, comprising both cohorts with initial single HCC ≤3 cm, 376 patients (67%) matched our criterion for predicting MVI.
Anatomical HR was carried out in 149 patients, partial HR in 227 patients, and survivals were compared to 52 patients matched our criterion who underwent RFA. Disease-free survival (DFS) and overall survival (OS) curves of these three groups are shown in Figure 1A and 1B, respectively. There were significant differences in both DFS and OS curves (P = .0478 and P = .0358, respectively). The 5-year DFS of the anatomical HR group reached 55%; however, the 5-year DFS of the RFA group was 28%. The 5-year OS of the anatomical HR group reached 61%, whereas that of the RFA group was 36%.
Multivariate analysis using Cox proportional hazard models identified five better prognostic factors (absence of transfusion, T-bil ≤1.0 mg/dL, age ≤65 years, ICGR15 ≤20%, and anatomical HR) influencing DFS, and three better prognostic factors (ICGR15 ≤20%, anatomical HR, and age ≤65 years) influencing OS (Table 8) . Anatomical HR led to significantly better survival in both disease-free (hazard ratio 0.689, P = .0231) and overall (hazard ratio 0.589, P = .0316) survivals.
T A B L E 3 Comparisons of tumor-related factors between the MVI (À) group and the MVI (+) group

| DISCUSSION
In the BCLC system, HCC ≤3 cm is considered to be "early stage", which denotes an early clinical entity with a high rate of cure. In both the BCLS system and the JSH-HCC guidelines, HR and RFA are equally recommended for HCC ≤3 cm. This is presumably based on the concept that HCC ≤3 cm is homogeneous and has low malignant potential. In our series, MVI was found in 168 patients (40.6%) among 414 patients with single HCC ≤3 cm, suggesting that the population of HCC ≤3 cm is not homogeneous, and that there may be a subgroup of an advanced biological nature with high-grade malignancy. We previously reported that MVI was also found in HCC ≤2 cm (very early stage in the BCLC system); however, its rate is low at 28.9%. 16 Among 244 patients with 2 cm ≤HCC ≤3 cm in our series, MVI was found in 115 patients (47.1%). This high rate would mean that 2 cm ≤HCC ≤3 cm has high-grade malignancy and, from our data, HR would be preferable to RFA for treating this subgroup.
We have reported that the elevation of DCP is a strong predictor for MVI of HCC. [16] [17] [18] DCP may have the ability to enhance cell proliferation by Met receptor and angiogenesis by vascular endothelial growth factor. 19, 20 Koike et al 21 carried out a prospective study to clarify the significance of DCP and concluded that DCP positivity was the strongest predictive factor for portal vein invasion. We know that DCP has not been measured worldwide; however, the significance of DCP elevation for predicting MVI in early HCC has been recognized in Western countries. 22 To establish personalized treatment for early HCC, measurement of DCP should be strongly recommended.
Although many reports refer to the superiority of DCP to AFP in predicting MVI in HCC, AFP is nevertheless another tool for evaluating the malignant potential of HCC. 23 In our series, the value of AFP itself had no correlation with MVI in HCC ≤3 cm; however, AFP ≥200 ng/mL had a significant correlation with MVI (+). The cut-off value of 200 ng/mL was from the appropriate value of 196 ng/mL identified by the ROC curve for predicting MVI in our first cohort.
Mild to moderate elevation of AFP is sometimes found in patients with hepatitis or cirrhosis, but severe elevation of AFP to levels of 200 ng/mL or more is likely to be caused by HCC with high malignant potential.
We previously reported that invasive gross type was the strongest predictor for MVI in HCC ≤2 cm. 16 In the present study, invasive gross type was also the strongest predictor for MVI in HCC ≤3 cm (odds ratio 13.68). Therefore, the preoperative diagnosis for HCC gross type should be another potent tool. We previously found that preoperative diagnosis for gross type of HCC ≤2 cm is highly challenging, because distinguishing between single nodular type with
F I G U R E 1 (A) Disease-free and (B) overall survival curves after anatomical hepatic resection (HR), partial HR, and radiofrequency ablation (RFA) in patients with hepatocellular carcinoma ≤3 cm matching our criterion for predicting microvascular invasion Limitations of the present study are its retrospective design; in addition, our results may be biased as a result of the physicians' varying therapeutic policies. Furthermore, patients' backgrounds, such as liver function reserves, differ among the anatomical HR, partial HR, and RFA groups. These differences may substantially affect survival after treatment. Propensity score matching is one of the potent methods to compare treatment modalities under homogeneous conditions; however, in our series, matching was very difficult because of the definite difference of liver functional reserve among the three groups. Therefore, randomized control study with the same therapeutic policies and the same patients' backgrounds will be necessary to confirm our results. Second, the specificity of our criterion for predicting MVI in HCC ≤3 cm was relatively low. Actual positive rate of MVI in this cohort was 35% (198 in 563 patients); therefore, there is a possibility of carrying out unnecessary anatomical HR in patients without MVI. We consider that "sensitivity" has more priority than "specificity" in this situation; however, a better criterion with high specificity should be discussed. Finally, in this study, the positive rates of MVI in HCC ≤3 cm considerably differed between the two institutions (40.6% vs 20.1%). This difference may be related to the characteristics of patients; however, there is no significant difference in the positive rates of poorly differentiated HCC (21.3 vs 20.8%, P = .9079). The same pathologist or pathological team did not examine MVI; however, pathologists of these two institutions are skilled experts because both institutions are high-volume centers of HR for HCC of over 100 cases per year. In addition, pathologists examined MVI according to the same published general rules. 13 We cannot show the reason there was a big difference in the positive rate of MVI in HCC ≤3 cm between the two institutions, but this difference itself would be a problem to be resolved by additional concerns of the pathological definitions of MVI for small-sized HCC.
In conclusion, matching at least one factor among three factors (tumor diameter ≥2 cm, AFP ≥200 ng/mL, or DCP ≥40 mAU/mL) can predict MVI in HCC ≤3 cm. In such patients, we recommend anatomical HR for better survival.
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